US Venture, Andera lead €32m series-B for HighLife

Following the deal, US Venture general partner Casey Tansey and Andera's Olivier Litzka will join the company's board.

The round also saw participation from previous backer Sofinnova Partners, new investor Sectoral Asset Management and the company's chair, Jose Calle Gordo.

Bryan Garnier & Co acted as private placement agent for the financing.

HighLife plans to use the fresh capital injected to complete the development of its trans-catheter trans-septal mitral valve implantation programme, which includes regulatory approval trials in Europe to obtain the CE mark and a first clinical trial in the US via an early feasibility study (EFS).

Previous funding
Sofinnova led a €12.3m series-A round for HighLife in October 2017. Following the deal, Sofinnova managing partner Antonie Papiernik joined the company's board.  

Company
Founded in 2010, HighLife specialises in the development of trans-catheter mitral valve replacement (TMVR) devices to treat patients suffering from mitral regurgitation. The company is based in Paris with an additional presence in California.

People
US Venture Partners – Casey Tansey (general partner).
Andera Partners – Olivier Litzka (partner).
Sofinnova Partners – Antonie Papiernik (managing partner).
HighLife – Georg Börtlein (founder, CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• France
• Healthcare
• Andera Partners
• Sofinnova Partners
• France
• Venture